Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Completed · Phase 2 · Has a placebo group

Conditions studied: Atrial Fibrillation

In brief

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

Key facts

Study ID
NCT00267930
Run by
Advanz Pharma
People needed
221
Starts
2005-12-01
Expected to finish
2006-08-01
Last updated by the study team
2008-12-18

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.